Sonoma Pharmaceuticals, Inc.
No enriched coverage for $SNOA in the last 7 days.
No SEC Form 4 filings for $SNOA in the last 30 days.
See all $SNOA insider activity →Sonoma Pharmaceuticals, Inc. (SNOA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Item 3.03 Material Modification to Rights of Security Holders. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On October 6, 2026, our board of directors approved, and we entered into, a Sec
Sonoma Pharmaceuticals, Inc. (SNOA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. Our annual meeting of stockholders was held on September 16, 2026. Proxies were solicited pursuant to our definitive proxy statement filed on July 28, 2026 with the Securities and Exchange Commission under Section 14
Sonoma Pharmaceuticals, Inc. (SNOA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On August 19, 2026, Sonoma Pharmaceuticals, Inc. (the “Company”) held an adjourned special meeting of stockholders (the “Special Meeting”), pursuant to a definitive proxy statement, filed with the Securities and Exch
Recent SNOA coverage spans corporate actions, financial news and earnings.
The rights agreement shields tax assets, reducing upside risk of an ownership‑change limitation.
The vote outcomes confirm existing governance and do not materially change the company's operations or capital structure.
Cancellation of the meeting may delay any pending shareholder actions and could signal governance concerns.
The quarter shows an inflection toward profitability, with revenue growth and margin expansion that can re-rate near-term expectations.
The print shows accelerating top-line growth with improving operating cash-earnings proxy (EBITDA loss narrowing), which can re-rate near-term risk for SNOA.
AlphAI scores every news story that mentions SNOA with an AI model for sentiment and relevance, and aggregates insider trades from Sonoma Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Sonoma Pharmaceuticals, Inc. (SNOA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Item 3.03 Material Modification to Rights of Security Holders. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On October 6, 2026, our board of directors approved, and we entered into, a Sec
1 min readSonoma Pharmaceuticals, Inc. (SNOA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. Our annual meeting of stockholders was held on September 16, 2026. Proxies were solicited pursuant to our definitive proxy statement filed on July 28, 2026 with the Securities and Exchange Commission under Section 14
1 min readSonoma Pharmaceuticals, Inc. (SNOA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On August 19, 2026, Sonoma Pharmaceuticals, Inc. (the “Company”) held an adjourned special meeting of stockholders (the “Special Meeting”), pursuant to a definitive proxy statement, filed with the Securities and Exch
1 min readSonoma Pharmaceuticals reported first-quarter revenue of $6.4 million, up from $4.0 million a year earlier, with U.S. sales up 141% to drive growth. Gross profit rose to $2.6 million (40% margin). EBITDA turned positive at $0.1 million versus a $1.0 million loss. Cash was $5.3 million as of June 30, 2026. Shares rose to $1.24 premarket.
4 min readSonoma Pharmaceuticals (Nasdaq:SNOA) reported fourth-quarter FY2026 results for the quarter ended March 31, 2026. Revenue rose to $5.6M (+48%) from $3.8M; gross profit was $2.2M (39%). Net loss was $0.6M, and EBITDA loss improved 66% to $0.2M. For FY2026, revenue increased to $19.5M (+$5.2M) and EBITDA loss fell 38% to $2.1M. Cash was $2.4M.
6 min readSonoma Pharmaceuticals has closed a public unit offering, raising approximately $3.5 million in net proceeds after expenses. The offering included units of common stock or pre-funded warrants, complemented by common stock purchase warrants, with each unit priced at $1.35. The funds are earmarked for general corporate purposes and working capital.
2 min readIf you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
3 min readIf you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
3 min read
